The NYHA classification was originally designed as a clinical and not a research tool. [7] It was never meant to serve the purpose of establishing the diagnosis of HF. It was designed purely as a ...
Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results